Paper17520680
Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease.
Jones RJ and 6 others. Int J Cancer, 2007. Cited by 53 papers, by iCite.
Cite this record
ConductScience Library. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Papers, record 17520680. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17520680
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Epstein-Barr Virus Infections | Major topic |
| Interleukin-6 | Major topic |
| Lymphoproliferative Disorders | Major topic |
| Tumor Virus Infections | Major topic |
| Animals | |
| Cell Line, Tumor | |
| DNA-Binding Proteins | |
| Enzyme-Linked Immunosorbent Assay | |
| Flow Cytometry | |
| Humans | |
| Immediate-Early Proteins | |
| Immunoblotting | |
| Interleukin-10 | |
| Mice | |
| Mice, SCID | |
| Reverse Transcriptase Polymerase Chain Reaction | |
| Time Factors | |
| Trans-Activators | |
| Viral Matrix Proteins | |
| Viral Proteins |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01-CA19014 | NCI NIH HHS | United States | P01CA019014 | PubMed and NIH | NIH RePORTER |
| R01-CA66519 | NCI NIH HHS | United States | R01CA066519 | PubMed and NIH | NIH RePORTER |
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42113877 | Playing both sides - Epstein-Barr Virus accumulates select cellular transcripts to counter virus-mediated host shut-off in lytic cells. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/42113877 | PubMed |
| 42023228 | The immunosuppressive tumor microenvironment in post-transplant lymphoproliferative disorder: pathogenesis and novel therapeutic frontiers. | Front Immunol | 2026 | https://conductscience.org/library/papers/42023228 | PubMed |
| 41835621 | EBV-dUTPase Modulates Host Immune Responses Potentially Altering the Tumor Microenvironment in EBV-associated Malignancies. | Curr Res HIV AIDS | 2016 | https://conductscience.org/library/papers/41835621 | PubMed |
| 41144108 | Multi-omics profiling uncovers paradoxical Epstein-Barr virus involvement in autoimmune liver disease pathogenesis. | AMB Express | 2025 | https://conductscience.org/library/papers/41144108 | PubMed |
| 36560713 | Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus. | Viruses | 2022 | https://conductscience.org/library/papers/36560713 | PubMed |
| 36242711 | The lytic phase of Epstein-Barr virus plays an important role in tumorigenesis. | Virus Genes | 2023 | https://conductscience.org/library/papers/36242711 | PubMed |
| 36113467 | Epstein-Barr virus: Biology and clinical disease. | Cell | 2022 | https://conductscience.org/library/papers/36113467 | PubMed |
| 35485636 | EBV genome variations enhance clinicopathological features of nasopharyngeal carcinoma in a non-endemic region. | Cancer Sci | 2022 | https://conductscience.org/library/papers/35485636 | PubMed |
| 34625709 | Calcium-dependent signalling in B-cell lymphomas. | Oncogene | 2021 | https://conductscience.org/library/papers/34625709 | PubMed |
| 34339458 | Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells. | PLoS Pathog | 2021 | https://conductscience.org/library/papers/34339458 | PubMed |
| 34073189 | An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness. | Viruses | 2021 | https://conductscience.org/library/papers/34073189 | PubMed |
| 33675667 | Epstein-Barr virus inactivates the transcriptome and disrupts the chromatin architecture of its host cell in the first phase of lytic reactivation. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33675667 | PubMed |
| 33228078 | Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. | Microorganisms | 2020 | https://conductscience.org/library/papers/33228078 | PubMed |
| 32847852 | Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta. | J Virol | 2020 | https://conductscience.org/library/papers/32847852 | PubMed |
| 32517128 | Oncogenic Properties of the EBV ZEBRA Protein. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32517128 | PubMed |
| 32059024 | B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection. | PLoS Pathog | 2020 | https://conductscience.org/library/papers/32059024 | PubMed |
| 30871092 | Novel Therapeutics for Epstein⁻Barr Virus. | Molecules | 2019 | https://conductscience.org/library/papers/30871092 | PubMed |
| 30052684 | A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. | PLoS Pathog | 2018 | https://conductscience.org/library/papers/30052684 | PubMed |
| 29899236 | Antiviral Drugs for EBV. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/29899236 | PubMed |
| 29723986 | EBV Positive Diffuse Large B Cell Lymphoma and Chronic Lymphocytic Leukemia Patients Exhibit Increased Anti-dUTPase Antibodies. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/29723986 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IL10 | 3586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17520680
GET https://conductscience.org/api/papers/v1/17520680/cited_by?page=2